Further to DB's response@umw:- Sidetracks are absolutely common...

First 20467 Last

Share
Profile

Follow
FrankASX

126 Posts.

20

03/05/24

16:39

Post #: 73655659
Share

Originally posted by Davy Boy: ↑

I'll start at the bottom.
A farm in with Clough who don't have any cash might have been a whole lot worse.
Now from the top.
OTC listing a fail? SM can't make outsiders buy shares. He did way over inflate its importance that's for sure but you can't blame him if no one preses the buy button....
PPSA sign fail. I agree to a point but again he can't make them sign.
Fail to understand how to raise $$. I think you are totally wrong there. He has raised over 100 million. I'm not sure how he could have done it differently?
maybe you could comment on how?
Fail in negotiating. Negotiating with who? The gov? Farm in? PAC and co?
The sp is where it is because of a failure to understand our registry is made up of retail mostly and the wrong type of insto's. Again SM can't make the right kind buy but IMO should have been paying much closer attention to those who were prepared to sell at the drop of a hat.
You can make no argument MK1 was a fail because of the sidetrack. That was a result of drilling the unknown.
You can make the argument that they cocked up at MK2 by drilling too deep, but even then they had independent advice on the pressures, which was wrong, so not totally to blame IMO.

Expand

Further to DB's response@umw:

- Sidetracks are absolutely common place particularly in wildcat drilling.

- SM is unparalleled among MD's at other ASX listed companies in terms of his accessibly and availably to individual shareholders.

IVZ Price at posting: 7.0¢ Sentiment: Buy Disclosure: Held
21 Upvote

0 Great analysis

Reply

Top Stories

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

NEU

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

CHM

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

NYR

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

There are more pages in this discussion • 2,419 more messages in this thread...

First 20467 Last

Add IVZ (ASX) to my watchlist

(20min delay)
Last 7.6¢		Change -0.001(1.30%)		Mkt cap ! $113.7M

Open	High	Low	Value	Volume
7.5¢	7.6¢	7.4¢	$72.39K	967.8K

Buyers (Bids)

No.	Vol.	Price($)
6	270320	7.4¢

Sellers (Offers)

Price($)	Vol.	No.
7.6¢	33492	1

View Market Depth

No.	Vol.	Price($)
6	270320	0.074
3	59931	0.073
3	84432	0.072
3	89050	0.071
5	396817	0.070

Price($)	Vol.	No.
0.076	33492	1
0.077	132987	2
0.078	254968	4
0.080	253368	6
0.081	7602	1

Last trade - 15.17pm 07/10/2024 (20 minute delay)

IVZ (ASX) Chart

Further to DB's response@umw:- Sidetracks are absolutely common...

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Further to DB's response@umw:- Sidetracks are absolutely common...

Top Stories

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News